Cannabigerol (CBG) is a new frontier in science. CBG is derived from the natural synthesis of the “mother of all cannabinoids,” cannabigerolic acid (CBGA), earning it many nicknames as well as interest from experts.
In maturing cannabis and hemp plants, enzymes synthesize CBGA into the chemical precursors for THC, CBD and other cannabinoids. Any CBGA left unsynthesized at the end of the plant’s growth cycle converts directly into CBG. This is usually only in trace amounts.
Most strains have a CBG content under 1%, though some plants can be crossbred to inhibit enzymatic activity and preserve higher levels of pure CBGA, resulting in CBG contents up to around 10%.
What does CBG do?
CBG was first isolated and synthesized in 1964, but as a rare cannabinoid, has yet to be the focus of significant research observation in humans. Its research has been studied widely using animal models.
Like other cannabinoids, CBG is processed by the body’s endocannabinoid system. It acts on the same receptors as THC, but with a lower affinity — the CB1 receptors in the central nervous system, and CB2 receptors in peripheral organs. Unlike THC, however, CBG doesn’t produce any psychoactive effects. For this reason, it’s sometimes referred to as an “inactive” counterpart to THC.
What makes this cannabinoid unique is its interaction at the α2-adrenergic receptor found in nerve endings, which manages the release of norepinephrine.
Exploratory research is currently in progress; however, in accordance with section 104.12(1) of the Cannabis Regulations, which pertains to health and cosmetic benefit claims, we are unable to comment on the outcomes and insights derived from studies that investigate the effects of CBG on human subjects.
How do we use CBG?
Kinloch Wellness delivers CBG in a balanced 1:1 blend with hemp-derived CBD throughout our Refresh product line, infused with terpenes with tropical and citrus flavours.
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish | Journal of the American Chemical Society (acs.org)
Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes - PMC (nih.gov)